Market Risers: European Metals Holdings Ltd, GlaxoSmithKline plc, KEFI Minerals plc

KEFI Minerals

The share price for European Metals Holdings Ltd ticker code: LON:EMH has gained 4.5% or 0.9 points during the course of today’s session so far. Buyers have stayed positive during this period. The period high has peaked at 20.9 dropping as low as 20.9. The number of shares traded by this point in time totalled 5,839 whilst the average number of shares exchanged is 182,770. The 52 week high for the share price is 57 amounting to 37 points in difference on the previous days close and a 52 week low being 16 is a variance of 4 points. European Metals Holdings Ltd now has a 20 moving average of 21.2 and now a 50 day simple moving average now at 21.14. Market capitalisation is now £29.64m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for European Metals Holdings Ltd being recorded at Wednesday, July 25, 2018 at 12:24:56 PM GMT with the stock price trading at 20.9 GBX.

 

 

Shares of GlaxoSmithKline plc ticker code: LON:GSK has stepped up 1.09% or 17 points in today’s trading session so far. Traders seem confident while the stock has been in play. The period high has peaked at 1597.8 and hitting a low of 1549.2. The total volume of shares exchanged so far has reached 4,521,525 whilst the daily average number of shares exchanged is just 9,808,607. The 52 week high price for the shares is 1606.5 amounting to 49.7 points different to the previous business close and a 52 week low sitting at 1179.39 making a difference of 377.41 points. GlaxoSmithKline plc has a 20 SMA of 1558.55 and now a 50 day moving average now of 1543.22. The current market capitalisation is £78,429.54m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Wednesday, July 25, 2018 at 12:51:45 PM GMT with the stock price trading at 1573.8 GBX.

 

The share price for KEFI Minerals plc found using EPIC: LON:KEFI has stepped up 8.37% or 0.18 points during today’s session so far. Buyers seem confident during the session. Range high for the period has seen 2.59 dipping to 2.15. Volume total for shares traded during this period was 2,156,084 with the daily average at 3,645,433. The 52 week high for the share price is 5.7 equating to 3.55 points difference from the previous close and the 52 week low at 2.15 making a difference of 0 points. KEFI Minerals plc now has a 20 SMA of 2.43 with a 50 day MA at 2.69. The current market capitalisation is £13.84m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for KEFI Minerals plc being recorded at Wednesday, July 25, 2018 at 12:21:52 PM GMT with the stock price trading at 2.33 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

KEFI Gold and Copper boosts Hawiah Project Mineral Resources by 26%

KEFI Gold and Copper Plc upgrades Hawiah Copper-Gold Project with a 26% increase in resources, highlighting significant potential in Saudi Arabia.

GSK Plc 5-in-1 meningococcal vaccine approved by FDA

GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.

KEFI Gold and Copper advances Tulu Kapi project launch with expanded financing

KEFI Gold and Copper plc updates on the Tulu Kapi Gold Project's launch in Ethiopia, expanding funds, and progressing community and financing efforts.

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.

Search

Search